Asian Liver Transplant Network Clinical Guidelines on Immunosuppression in Liver Transplantation

Most management guidelines and much of the available clinical trial evidence for immunosuppressants in liver transplantation pertain to Western practice. While evidence from Western studies may not translate to Asian settings, there is a paucity of Asian randomized controlled trials of immunosuppression in liver recipients. Nonetheless, there are notable differences in the indications and procedures for liver transplantation between Western and Asian settings. The Asian Liver Transplant Network (ALTN) held its inaugural meeting in Singapore in November 2016 and aimed to provide an Asian perspective on aspects of immunosuppression following liver transplantation. Because of their importance to outcome following liver transplantation, the meeting focused on: (1) reducing the impact of renal toxicity, (2) hepatocellular carcinoma recurrence and (3) nonadherence with immunosuppressant therapy. Corresponding author: Poh Seng TAN, Division of Gastroenterology and Hepatology, National University Hospital, National University Health System, 1E Kent Ridge Road Tower Block, Level 10, Singapore 119228, DID (+65) 6772-4354; Fax (+65) 6775-1518, Email: poh_seng_tan@nuhs.edu.sg Authorship page Authorship P.S.T., M.D.M., and T.K. are co-first authors with equal contribution to writing the draft of the article. J.F., and K.L. are co-senior authors with equal contribution leading the project. All authors reviewed the draft, provided expertise for critical revisions, and approved the final version of the article. Disclosure P.S.T is a PI of a Novartis sponsored clinical trial (H2307). The other authors declare no conflict of interest. Funding The consensus meeting was supported by the educational grant provided by Novartis and Astellas. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.

https://ift.tt/2K1amfP